Fresh US economic readings, a $675 million industrial-technology acquisition and new biotech developments broadened Monday’s market agenda beyond index movements. The October 26, 2026 news flow also included an AI infrastructure agreement, financing for drone communications and healthcare takeover speculation.
1. Chicago Fed Activity Index Returns Above Zero
The Chicago Fed National Activity Index increased to +0.07 in September from a revised −0.08 in August, according to Monday’s release. Its three-month average rose to +0.03 from +0.01. Production strengthened, while consumption and housing made a negative contribution. The reading indicates activity slightly above its historical trend, offering a more balanced growth signal than a uniformly strong expansion.
2. Dallas Fed Survey Shows Slower Factory Growth
October’s Texas manufacturing survey showed the production index falling to 15.8 from 29.5 and new orders declining to 9.3 from 30.7. However, general business activity improved to 13.4 from 9.8. Raw-material price pressures increased. The divergence suggests continued factory expansion with weaker momentum, while cost pressures remain relevant to industrial margins. This regional survey does not measure the entire US economy.
3. Acuity Agrees to Buy Parameter for $675 Million
Parameter Technologies announced a definitive agreement to be acquired by Acuity for $675 million. Parameter would join Distech Controls within Acuity Intelligent Spaces, combining sensing, detection and monitoring with building controls. The companies highlighted data-center applications and earlier detection of equipment problems. Closing is expected in late 2026, subject to customary conditions, including the antitrust waiting period.
Also Read: Top US Earnings Today: Cadence, Celestica and Nucor Deliver Stronger Sales
4. Verizon Signs $2 Billion-Plus AWS Agreement
Verizon announced an agreement valued at more than $2 billion with Amazon Web Services, establishing a commercial framework to scale distributed computing for agentic and generative AI workloads. The announcement extends the AI infrastructure story into connectivity and network services. The agreement’s stated value should be distinguished from revenue already recognized; its commercial framework supports future deployment rather than documenting completed delivery.
5. Corxel Plans Nasdaq Route Through Amanat Merger
Corxel US and Amanat Acquisition announced a definitive business combination agreement. The proposed transaction includes approximately $300 million in PIPE commitments and targets about $377 million in gross proceeds before costs, assuming no shareholder redemptions. Closing is expected in the first half of 2027. Funding would support development of investigational oral obesity therapies, including the planned Phase 3 program for CX11.
6. Peraso Secures Strategic Drone-Communications Financing
Peraso agreed to an approximately $10 million private placement with NantCapital to support development and commercialization of advanced communications, including drone applications. Expected closing is around October 28, subject to conditions. The financing includes common shares, pre-funded warrants and accompanying warrants. It adds development resources while introducing potential dilution; the announcement does not establish future customer orders or commercial adoption.
7. Surgery Partners Rallies on Reported Takeover Talks
Surgery Partners rose 20.6% to $19 in a Monday premarket snapshot following reports that Bon Secours Mercy Health was in late-stage talks to acquire a majority stake in a transaction valued around $6 billion. The reported discussions drew attention to healthcare consolidation. These remain reported negotiations rather than a confirmed signed acquisition, and the quoted price movement is not Monday’s closing return.
Also Read: S&P 500 Today, October 26, 2026: Nasdaq Leads Wall Street Rally as AI Stocks Recover
8. Xencor Gains After Kidney-Cancer Trial Update
Xencor climbed 27.1% to $32 in Monday premarket trading after Sunday’s XmAb819 update. At the proposed 400-microgram-per-kilogram dose, five of 11 evaluable patients had confirmed partial responses. The company plans further development and regulatory discussions. The small early-stage cohort limits conclusions about eventual approval, and safety remains important: Grade 3 or higher related adverse events occurred in 72.1% of expansion-cohort patients.
9. Oruka Reports New Psoriasis Trial Results
Oruka reported that 61% of patients in the high-dose group achieved complete skin clearance at week 16 in the Phase 2b EVERLAST-B trial, compared with none receiving placebo. The company plans Phase 3 studies in the first half of 2027, pending regulatory discussions. The results support further development, while longer follow-up is needed to assess durability and safety.
10. Linde Declares Fourth-Quarter Dividend
Linde’s board declared a quarterly dividend of $1.60 per share, payable December 17 to shareholders of record on December 3, 2026. The announcement establishes the next distribution timetable for the Nasdaq-listed industrial-gases company. It is a capital-return development rather than an earnings release, and the declaration alone does not indicate a dividend increase or a change in operating performance.
OneTrader Financial Disclaimer
This article is published by OneTrader for informational and educational purposes only. It does not constitute financial advice, investment recommendations or an invitation to buy, sell or hold any securities. Market prices and financial information may change after publication. Readers should independently verify financial information and consult a qualified financial adviser before making investment decisions. Investing in financial markets involves risk, including the potential loss of invested capital.
Also Read: Top US Earnings Today, October 26, 2026: Verizon Raises Outlook as Medifast Restructures
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.
